GlassScriptPhysician profile
Stacy Weeks Weaver
NPI 1609127075
$3,132.27
in general payments reported to CMS, 2019-2025
41 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,201 · 2022: $822 · 2023: $502 · 2024: $302 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343.09 | 2021-2024 | Farxiga, Andexxa, Breztri |
| Lilly USA, LLC | $291.96 | 2021-2023 | Mounjaro, Jardiance |
| Abbvie INC. | $259.04 | 2021-2023 | |
| Esperion Therapeutics, INC. | $240.22 | 2021-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $179.30 | 2022-2023 | |
| Davol INC. | $170.48 | 2024 | Phasix Mesh |
| Glaxosmithkline, LLC. | $166.41 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $119.36 | 2021-2023 | Trintellix |
| Pfizer INC. | $107.82 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $99.84 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.19 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.31 | 2022 | |
| Novo Nordisk INC | $73.76 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $72.34 | 2021 | |
| Amarin Pharma, INC. | $58.97 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $58.50 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57.68 | 2021-2025 | Keytruda |
| Janssen Pharmaceuticals, INC | $50.61 | 2021-2024 | Xarelto |
| Xeris Pharmaceuticals, INC. | $50.19 | 2022-2023 | Gvoke Hypopen |
| Smith+Nephew, INC. | $49.33 | 2025 | Grafix |
| Angiodynamics, INC. | $41.33 | 2025 | Alphavac |
| Zealand Pharma US, INC. | $37.88 | 2021-2022 | |
| Eisai INC. | $35.56 | 2021 | |
| Cordis US Corp. | $35.06 | 2025 | Mynx Control Venous |
| Antares Pharma, INC. | $32.94 | 2022 | |
| Lemaitre Vascular, INC. | $32.46 | 2025 | Restoreflow |
| Octapharma USA, INC. | $31.31 | 2025 | Fibryga |
| Kowa Pharmaceuticals America, INC. | $29.84 | 2021-2023 | Seglentis, Livalo |
| Endologix LLC | $28.82 | 2024-2025 | Endocross Device, Torus Stent Graft System, Afx2 Bifurcated Endograft System |
| Atricure, INC. | $28.72 | 2025 | Atricure Cryoice Cryoablation System (Cryo2) |
| Terumo Medical Corporation | $28.11 | 2025 | Angio-Seal, Metacross Otw |
| Hikma Pharmaceuticals USA | $25.11 | 2022 | |
| Horizon Therapeutics Plc | $23.22 | 2021 | |
| Genentech USA, INC. | $18.13 | 2021 | |
| Becton, Dickinson and Company | $16.34 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.18 | 2023 | Qelbree |
| Pacira Pharmaceuticals Incorporated | $14.38 | 2024 | Exparel |
| Abbott Laboratories | $14.06 | 2021 | |
| Tolmar, INC. | $12.76 | 2023 | |
| Shield Therapeutics INC | $12.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.